COVID-19 UPDATE

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

News Releases

News Releases

Date
Title
Document
December 23, 2014
ENDO PHARMACEUTICALS AND BIODELIVERY SCIENCES ANNOUNCE NDA SUBMISSION FOR BUPRENORPHINE HCl BUCCAL FILM FOR THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN
PDF Version
December 10, 2014
BioDelivery Sciences Launches InReach Support Program for Those Affected by Opioid Dependence
PDF Version
December 8, 2014
BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
PDF Version
November 25, 2014
BioDelivery Sciences to Present at the 26th Annual Piper Jaffray Healthcare Conference
PDF Version
November 7, 2014
BioDelivery Sciences to Present at the Credit Suisse 2014 Healthcare Conference
PDF Version
November 5, 2014
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2014 Financials
PDF Version
November 3, 2014
BioDelivery Sciences to Present at the Stifel 2014 Healthcare Conference and the Jefferies 2014 Global Healthcare Conference
PDF Version
November 3, 2014
BioDelivery Sciences Announces the Availability of BUNAVAIL™ in the U.S.
PDF Version
October 28, 2014
BioDelivery Sciences to Develop a Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik for Use in Opioid Dependence and Pain
PDF Version
October 10, 2014
BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance
PDF Version

Investor Presentation

More information is coming soon.


Upcoming Events

BioDelivery Sciences International Investor Day
 Oct 14, 2021 at 10:30 AM EDT

Stay Connected

Stay up to date on the latest news

Get started now
October 1, 2021 /
Data provided by West LLC. Minimum 15 minutes delayed.